Literature DB >> 11083276

Expression of osteoclast differentiation factor in rheumatoid arthritis.

Y Shigeyama1, T Pap, P Kunzler, B R Simmen, R E Gay, S Gay.   

Abstract

OBJECTIVE: To analyze the expression pattern of osteoclast differentiation factor (ODF) and its contribution to osteoclastogenesis in rheumatoid arthritis (RA).
METHODS: The expression of ODF was analyzed by reverse transcriptase-polymerase chain reaction (RT-PCR) in RA synovial fibroblasts (RASF) isolated from 7 RA patients and in normal skin fibroblasts. Using RNA probes specific for ODF, in situ hybridization was performed. Immunohistochemical double labeling for CD68 was applied to characterize the ODF-expressing cells. ODF protein and messenger RNA (mRNA) expression by RASF with or without 1,25(OH)2D3 was studied by Western blot analysis and quantitative real-time PCR. In addition, we performed coculture experiments with RASF and normal peripheral blood mononuclear cells with or without 1,25(OH)2D3.
RESULTS: By RT-PCR, ODF mRNA expression was found in all RASF investigated, but not in normal skin fibroblasts. In situ hybridization revealed that in RA synovial tissues, ODF mRNA was expressed mainly in the lining layer and at sites where synovium was attached to bone. Immunohistochemical double labeling demonstrated ODF mRNA expression mainly in CD68-fibroblast-like synoviocytes and CD68+ multinucleated osteoclast-like cells. By Western blotting, all RASF expressed ODF protein. However, different levels of ODF expression were found in the RASF from different patients. Interestingly, RASF expressing higher levels of ODF induced a larger number of osteoclast-like cells than did RASF expressing only low levels of ODF. Although 1,25(OH)2D3 did not alter the levels of ODF expression in RASF on either Western blot or quantitative real-time PCR, osteoclastogenesis required the presence of 1,25(OH)2D3.
CONCLUSION: The present results suggest that activated RASF, by expressing ODF, play an important role in rheumatoid bone destruction. Moreover, the data provide evidence that RASF not only activate osteoclasts, but also contribute directly to osteoclastogenesis.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11083276     DOI: 10.1002/1529-0131(200011)43:11<2523::AID-ANR20>3.0.CO;2-Z

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  72 in total

Review 1.  Role of nuclear factor kappaB in synovial inflammation.

Authors:  Ulf Müller-Ladner; Renate E Gay; Steffen Gay
Journal:  Curr Rheumatol Rep       Date:  2002-06       Impact factor: 4.592

Review 2.  Are fibroblasts involved in joint destruction?

Authors:  T Pap; I Meinecke; U Müller-Ladner; S Gay
Journal:  Ann Rheum Dis       Date:  2005-11       Impact factor: 19.103

3.  Tumour necrosis factor blockers and structural remodelling in ankylosing spondylitis: what is reality and what is fiction?

Authors:  Georg Schett; Robert Landewé; Désirée van der Heijde
Journal:  Ann Rheum Dis       Date:  2007-06       Impact factor: 19.103

Review 4.  Joint remodelling in inflammatory disease.

Authors:  Georg Schett
Journal:  Ann Rheum Dis       Date:  2007-11       Impact factor: 19.103

5.  Stimulation of osteoclast formation by inflammatory synovial fluid.

Authors:  Iannis E Adamopoulos; Lynett Danks; Ichiro Itonaga; Rachel M Locklin; Afsie Sabokbar; David J P Ferguson; Nicholas A Athanasou
Journal:  Virchows Arch       Date:  2006-04-21       Impact factor: 4.064

6.  Synovial macrophage-osteoclast differentiation in inflammatory arthritis.

Authors:  L Danks; A Sabokbar; R Gundle; N A Athanasou
Journal:  Ann Rheum Dis       Date:  2002-10       Impact factor: 19.103

7.  Interleukin-35 upregulates OPG and inhibits RANKL in mice with collagen-induced arthritis and fibroblast-like synoviocytes.

Authors:  Y Li; D Li; Y Li; S Wu; S Jiang; T Lin; L Xia; H Shen; J Lu
Journal:  Osteoporos Int       Date:  2015-11-16       Impact factor: 4.507

8.  Inhibitory effects of ZSTK474, a novel phosphoinositide 3-kinase inhibitor, on osteoclasts and collagen-induced arthritis in mice.

Authors:  Shoko Toyama; Naoto Tamura; Kazuhiko Haruta; Takeo Karakida; Shigeyuki Mori; Tetsuo Watanabe; Takao Yamori; Yoshinari Takasaki
Journal:  Arthritis Res Ther       Date:  2010-05-18       Impact factor: 5.156

Review 9.  Osteoimmunology in rheumatic diseases.

Authors:  Georg Schett
Journal:  Arthritis Res Ther       Date:  2009-01-30       Impact factor: 5.156

10.  Prevention of bone mineral density loss in patients with rheumatoid arthritis treated with anti-TNFalpha therapy.

Authors:  Hubert Marotte; Pierre Miossec
Journal:  Biologics       Date:  2008-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.